Biotechnology Firm Advances Cardio Proactive Candidate toward Phase 2a Clinician Evaluation
Published: 18 Mar 2026
Author: Precedence Research
Nyrada Inc., a prominent player in biotechnology, is preparing to initiate a Phase 2a clinical trial for its lead candidate, Xolatryp, a cardioprotective agent. This investigational therapy targets ischemia-reperfusion injury, a significant complication associated with acute myocardial infarction, particularly the damage that occurs upon reperfusion of ischemic myocardium. Given the challenges this type of injury presents in modern cardiology, Xolatryp aims to mitigate myocardial damage resulting from the restoration of blood flow to oxygen-starved cardiac tissue.
Percutaneous coronary intervention (PCI) is often applied in acute ST-elevation myocardial infarction (STEMI), which is a procedure aimed at providing blood supply quickly, directing the reopening of closed coronary arteries. Though PCI is very effective in restoring the circulation, the abrupt flow of oxygenated blood can cause a cascade of biochemical reactions, which is likely to aggravate the injury of cells in the heart. There are currently few therapeutic interventions that are specifically developed to safeguard cardiac tissue at this critical stage of treatment and hence address a significant medical need.
According to Precedence research, the global ischemia-reperfusion injury treatment market was estimated at USD 1.12 billion in 2025 and is projected to increase from USD 1.19 billion in 2026 to approximately USD 2.07 billion by 2035, expanding at a CAGR of 6.32% from 2026 to 2035. The ischemia reperfusion injury (IRI) therapy market is dedicated to the development of therapies aimed at the reduction of the tissue damage that develops when the blood supply to the organs is restored after a certain duration of ischemia or lack of oxygen.
Xolatryp is a new small-molecule agent that has been designed to provide cardioprotective effects in myocardial cells in case of acute myocardial ischemic conditions. The drug is aimed at the inhibition of abnormal influx of calcium mediated by TRPC ion channels, which is thought to have a major role in the damage to the cells that comes with the reperfusion. The therapy would stabilize the cardiac cells' activity by regulating this pathway, which would minimize the levels of oxidative stress as well as the level of myocardial damage during reperfusion therapy.
The proposed Phase 2A study is designed as a randomized, binary, placebo-controlled, multicentre clinical trial. We anticipate enrolling approximately 200 patients diagnosed with ST-Elevation Myocardial Infarction (STEMI) who are undergoing Percutaneous Coronary Intervention (PCI) procedures. Participants will be administered either the investigational therapy or a placebo via intravenous infusion. This design will facilitate a comparison of the safety profile and preliminary efficacy of the drug under investigation.
Some of the exploratory clinical endpoints that researchers will study will include the infarct size in cardiac magnetic resonance imaging, cardiac biomarker concentrations, including troponin, and arrhythmia that occur after treatment. The results will allow to assess how effective the therapy can be used to minimize myocardial damage and aid in better recovery after acute cardiac events.
Xolatryp has the potential to enhance cardioprotective strategies significantly, contingent upon favourable results from ongoing clinical trials. These developments highlight the increasing focus within the biotechnology and pharmaceutical sectors on the development of targeted therapies aimed at addressing the complex molecular pathways involved in ischemia-reperfusion injury.